An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) With and Without CNS Manifestations
Phase of Trial: Phase 0
Latest Information Update: 17 Jun 2019
Price : $35 *
At a glance
- Drugs Tolcapone (Primary)
- Indications Amyloidosis
- Focus Pharmacodynamics; Proof of concept
- 12 Jun 2019 Status changed from active, no longer recruiting to completed.
- 30 Apr 2019 Planned End Date changed from 1 May 2019 to 1 Jun 2019.
- 30 Apr 2019 Planned primary completion date changed from 1 Apr 2019 to 30 May 2019.